Non-invasive imaging of plaque vulnerability: an important tool for the assessment of agents to stabilise atherosclerotic plaques.

Abstract:

:Disruption of a vulnerable atherosclerotic plaque is well-recognised as the primary cause of stroke, non-fatal myocardial infarction and sudden cardiac death. Novel therapeutic agents are being developed to stabilise such plaques. The initial evaluation of these drugs would be facilitated by the use of non-invasive imaging techniques to identify vulnerable plaque and document serial changes in plaque stability. The aim of this review is to explain the characteristics of the leading non-invasive imaging modalities and discuss their role in examining the vulnerable plaque. This knowledge will be extremely important for physicians and scientists involved in the clinical evaluation of novel agents to stabilise the vulnerable plaque.

authors

Sosnovik DE,Muller JE,Kathiresan S,Brady TJ

doi

10.1517/13543784.11.5.693

subject

Has Abstract

pub_date

2002-05-01 00:00:00

pages

693-704

issue

5

eissn

1354-3784

issn

1744-7658

journal_volume

11

pub_type

杂志文章,评审
  • Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse. Therefore, for the past few years, development of targete...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1312338

    authors: Vangapandu HV,Jain N,Gandhi V

    更新日期:2017-05-01 00:00:00

  • LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action.

    abstract::Two classes of luteinising hormone-releasing hormone (LHRH) analogues have been developed so far to be used for oncological therapies: LHRH agonists and antagonists. LHRH agonists are widely and successfully used for the management of steroid-dependent malignancies. Chronic administrations of these compounds result in...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.4.709

    authors: Limonta P,Montagnani Marelli M,Moretti RM

    更新日期:2001-04-01 00:00:00

  • Pharmacology of argatroban.

    abstract::Argatroban, a synthetic peptidomimetic antithrombin agent, is the first clinical anticoagulant solely to target thrombin. For some time, this drug has been used in Japan for the management of thromboembolic disorders. Recently, it has been approved in Japan for use in thrombotic and ischaemic stroke. Despite a large n...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.5.625

    authors: Jeske W,Walenga JM,Lewis BE,Fareed J

    更新日期:1999-05-01 00:00:00

  • Olpadronate: a new amino-bisphosphonate for the treatment of medical osteopathies.

    abstract::Olpadronate is a nitrogenated bisphosphonate. Although it shares the therapeutic and pharmacological properties of pamidronate and alendronate, it has a greater dosage amplitude, more predictable effects and a greater digestive tolerability than other bisphosphates. Therefore, it may be more appropriate in the treatme...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.9.1521

    authors: Roldán EJ,Pérez-Llore A,Ferretti JL

    更新日期:1998-09-01 00:00:00

  • Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators.

    abstract::CGRP is a potent vasodilator that has been shown to have a physiological and/or pathological role in neurogenic inflammation, headaches including migraine, thermal injury, circulatory shock, pregnancy and menopause, hypertension and heart failure and is known to be cardioprotective. CGRP is also a positive inotrope an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.6.1131

    authors: Doggrell SA

    更新日期:2001-06-01 00:00:00

  • Recombinant toxins in haematologic malignancies and solid tumours.

    abstract::Recombinant toxins constitute a new modality for the treatment of cancer, since they target cells displaying specific surface-receptors or antigens. They are fusion proteins, which contain toxin and ligand regions, and are produced in Escherichia coli. The ligand may be a growth factor or a fragment of an antibody, an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.9.1405

    authors: Kreitman RJ

    更新日期:1998-09-01 00:00:00

  • Inhibitors of cholesteryl ester transfer protein--a new approach to coronary artery disease.

    abstract::Despite the use of the statins to lower low-density lipoprotein-cholesterol, leading to major reductions in the mortality and morbidity that is associated with coronary artery disease, considerable mortality and morbidity remains. Increasing high-density lipoprotein (HDL)-cholesterol levels has been associated with re...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.15.2.99

    authors: Doggrell SA

    更新日期:2006-02-01 00:00:00

  • Recent advances in the management of adult myositis.

    abstract::Standard drug therapy of adult polymyositis, dermatomyositis and inclusion body myositis includes high-dose corticosteroids and cytotoxic drugs (methotrexate, azathioprine (AZA) and cyclophosphamide). Recent data are in favour of the early introduction of a cytotoxic or immunomodulating drug in addition to corticoster...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.10.7.1265

    authors: Fam AG

    更新日期:2001-07-01 00:00:00

  • Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.

    abstract:INTRODUCTION:Type 2 diabetes is a chronic metabolic disease characterized by persistent hyperglycemia resulting from progressive deficient of insulin in patients with a background of insulin resistance. Current treatment algorithms recommended by American Diabetes Association/The European Association for the Study of D...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2017.1360274

    authors: Tan X,Cao X,Zhou M,Zou P,Hu J

    更新日期:2017-09-01 00:00:00

  • Ticagrelor for the treatment of peripheral arterial disease.

    abstract:INTRODUCTION:Peripheral arterial disease (PAD) is a manifestation, and marker of severity, of a generalized atherosclerotic process. Antiplatelet therapy is recommended to prevent cardiovascular events but much of the evidence to support this is drawn from studies on older drugs. AREAS COVERED:In this review, the auth...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2014.974803

    authors: Chong AY,So DY

    更新日期:2014-12-01 00:00:00

  • Targeting tyrosine-kinases in ovarian cancer.

    abstract:INTRODUCTION:Epithelial ovarian cancer (EOC) is the leading cause of gynaecologic cancer death. Although in some cases initial treatment is effective, most of the women diagnosed with EOC will probably need medical treatment for their disease. There is a critical need to develop effective new strategies for the managem...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2013.816282

    authors: Morotti M,Becker CM,Menada MV,Ferrero S

    更新日期:2013-10-01 00:00:00

  • Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.

    abstract:IMPORTANCE OF THE FIELD:Aspirin, an irreversible inhibitor of thromboxane A(2) production, in combination with clopidogrel, an inhibitor of PY(12) ADP platelet receptors, represents the current standard-of-care of antiplatelet therapy for patients with acute coronary syndrome and those undergoing percutaneous coronary ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.521741

    authors: Tomasello SD,Angiolillo DJ,Goto S

    更新日期:2010-12-01 00:00:00

  • Cardiac fibrosis: emerging agents in preclinical and clinical development.

    abstract:INTRODUCTION:Myocardial fibrosis is a remarkably dynamic process mediated by different molecular pathways that represent potential targets of novel therapeutic interventions. Transforming Growth Factor-beta (TGF-β), connective Tissue Growth Factor (cTGF) and Galectin-3 (Gal-3) represent the most promising targets on wh...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1080/13543784.2021.1868432

    authors: Spoladore R,Falasconi G,Fiore G,Di Maio S,Preda A,Slavich M,Margonato A,Fragasso G

    更新日期:2021-01-04 00:00:00

  • Aromatase inhibitors for the treatment of infertility.

    abstract::Ovarian stimulation during infertility treatment is used either alone or in conjunction with intrauterine insemination and assisted reproductive technologies. At the present time, the two main medications used for ovarian stimulation include an oral antioestrogen, clomiphene citrate and injectable gonadotrophins. In s...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.12.3.353

    authors: Mitwally MF,Casper RF

    更新日期:2003-03-01 00:00:00

  • Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine?

    abstract:IMPORTANCE OF THE FIELD:Migraine is an episodic, substantially inherited brain disorder affecting 15% of adults in Western Europe and North America, and is one of the commonest reasons for patients to see their physicians. While the World Health Organization considers that severe migraine can be as disabling as quadrip...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543781003691832

    authors: Marin JC,Goadsby PJ

    更新日期:2010-04-01 00:00:00

  • Gene therapy for Parkinson's disease: review and update.

    abstract::Gene transfer technology is under exploration to find therapies for the treatment of Parkinson's disease (PD) and other neurodegenerative disorders. The technology of genetic transfer can also be used as a neurobiological tool to understand the role of various genes in animal models of neurodegeneration. We describe t...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.8.10.1551

    authors: Frim DM,Kang UJ

    更新日期:1999-10-01 00:00:00

  • Current drugs and medical treatment algorithms in the management of acute decompensated heart failure.

    abstract:BACKGROUND:Acute decompensated heart failure (ADHF) is associated with increased hospitalization rates and high in-hospital mortality, and has emerged as a major public health problem over the past decade. In recent years, several new drugs and therapeutic approaches have failed to reduce short- and long-term morbidity...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543780902922660

    authors: Triposkiadis F,Parissis JT,Starling RC,Skoularigis J,Louridas G

    更新日期:2009-06-01 00:00:00

  • Therapeutic developments in multiple sclerosis.

    abstract::Recently there have been considerable advances made in the treatment of multiple sclerosis. For the first time since its initial clinical description in the 1800s, there are now available several medications which unequivocally exert favourable clinical effects through the lowering of the biological activity of the hu...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.4.655

    authors: Goodin DS

    更新日期:2000-04-01 00:00:00

  • The therapeutic potential of testosterone patches.

    abstract::In the last decade, transdermal delivery of testosterone (T) has been shown to be a safe and effective means of treating male hypogonadism. Transdermal T patches can provide for physiologic androgen replacement in over 90% of men with hypogonadism. In addition, T patches have been shown to be equivalent to im. T ester...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.12.1977

    authors: Amory JK,Matsumoto AM

    更新日期:1998-12-01 00:00:00

  • Tirofiban: an investigational platelet glycoprotein IIb/IIIa receptor antagonist.

    abstract::The deposition of a platelet rich thrombus on an atherosclerotic plaque is a critical step in the development of unstable coronary syndromes. Currently available therapeutic agents such as aspirin and ticlopidine are relatively weak inhibitors of platelet aggregation. Recently, antagonists to platelet glycoprotein IIb...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.6.9.1257

    authors: Kumar A,Herrmann HC

    更新日期:1997-09-01 00:00:00

  • Current Role of Dacomitinib in Head and Neck Cancer.

    abstract:INTRODUCTION:Recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) has a dismal prognosis. With the emergence of monoclonal antibodies and tyrosine kinase inhibitors (TKI) targeting the epidermal growth factor receptor (EGFR), several drugs were developed and tested in HNSCC. To date, the monoclonal...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2016.1177022

    authors: Elicin O,Ozsahin M

    更新日期:2016-06-01 00:00:00

  • Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

    abstract::Sitagliptin is a once-daily, orally active, competitive and fully reversible inhibitor of dipeptidyl peptidase 4, the enzyme that is responsible for the rapid degradation of the incretin hormone glucagon-like peptide-1. It is the first in this new class of antihyperglycaemic agents to gain regulatory approval for the ...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.4.533

    authors: Deacon CF

    更新日期:2007-04-01 00:00:00

  • TNP-470: an angiogenesis inhibitor in clinical development for cancer.

    abstract::TNP-470, an analogue of fumagillin, has been shown to inhibit angiogenesis in vitro and in vivo. In 1992, TNP-470 entered clinical development for cancer as an anti-angiogenic agent. It is currently in Phase I/II trials in Kaposi's sarcoma, renal cell carcinoma, brain cancer, breast cancer, cervical cancer and prostat...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.9.6.1383

    authors: Kruger EA,Figg WD

    更新日期:2000-06-01 00:00:00

  • Skin substitutes to enhance wound healing.

    abstract::Biologically-based skin substitutes have developed as commercial products over the last 5 years. The first generation includes the collagen-based synthetic device, Integra, and Alloderm, which is based on devitalised and cross-linked human dermis. These are used as dermal replacements for third degree burns. Within th...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章

    doi:10.1517/13543784.7.5.803

    authors: Mansbridge J

    更新日期:1998-05-01 00:00:00

  • PTI-821: sustained-release oxycodone using gel-cap technology.

    abstract::PTI-821 is a long-acting formulation of oxycodone that is intended to deter abuse through its gel-cap technology. Produced by Pain Therapeutics in alliance with King Pharmaceuticals, PTI-821 is designed to provide strong pain relief with the intent of offering greater safety than is presently available from convention...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.16.3.359

    authors: Webster LR

    更新日期:2007-03-01 00:00:00

  • Metastatic melanoma: therapeutic agents in preclinical and early clinical development.

    abstract::Introduction: Advanced melanoma historically had a very poor outcome but targeted therapies and immune checkpoint inhibitors (IC) have changed the course of the disease and made durable responses possible. However, most patients will develop progressive disease, so further strategies to overcome treatment resistance a...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2020.1769066

    authors: Boos LA,Leslie I,Larkin J

    更新日期:2020-07-01 00:00:00

  • Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers.

    abstract::Introduction: Neuropathic pain is a chronic condition that significantly affects the quality of life of millions of people globally. Most of the pharmacologic treatments currently in use demonstrate modest efficacy and over half of all patients do not respond to medical management. Hence, there is a need for new, effi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1080/13543784.2020.1728254

    authors: Kushnarev M,Pirvulescu IP,Candido KD,Knezevic NN

    更新日期:2020-03-01 00:00:00

  • Berberine: a potential phytochemical with multispectrum therapeutic activities.

    abstract:IMPORTANCE OF THE FIELD:The use of traditional medicines of natural origin is being encouraged for the treatment of chronic disorders, as synthetic drugs in such cases may cause unpredictable adverse effects. Berberine, a traditional plant alkaloid, is used in Ayurvedic and Chinese medicine for its antimicrobial and an...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2010.517745

    authors: Vuddanda PR,Chakraborty S,Singh S

    更新日期:2010-10-01 00:00:00

  • Investigational therapies for Ewing sarcoma: a search without a clear finding.

    abstract:INTRODUCTION:Ewing sarcoma family tumors (ESFT) are a group of aggressive diseases, characterized histologically by small, round, blue cells and genetically by translocation involving EWS and ETS partner genes. The current treatment of localized Ewing sarcoma (ES) requires a multi-disciplinary approach, including multi...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.2016.1168398

    authors: Vornicova O,Bar-Sela G

    更新日期:2016-06-01 00:00:00

  • The therapeutic potential of the cannabinoids in neuroprotection.

    abstract::After thousands of years of interest the last few decades have seen a huge increase in our knowledge of the cannabinoids and their mode of action. Their potential as medical therapeutics has long been known. However, very real concerns over their safety and efficacy have lead to caution and suspicion when applying the...

    journal_title:Expert opinion on investigational drugs

    pub_type: 杂志文章,评审

    doi:10.1517/13543784.11.10.1365

    authors: Grundy RI

    更新日期:2002-10-01 00:00:00